197 related articles for article (PubMed ID: 37886930)
1. Targeted Delivery of Chimeric Antigen Receptor into T Cells via CRISPR-Mediated Homology-Directed Repair with a Dual-AAV6 Transduction System.
Moço PD; Farnós O; Sharon D; Kamen AA
Curr Issues Mol Biol; 2023 Sep; 45(10):7705-7720. PubMed ID: 37886930
[TBL] [Abstract][Full Text] [Related]
2. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing.
Balke-Want H; Keerthi V; Gkitsas N; Mancini AG; Kurgan GL; Fowler C; Xu P; Liu X; Asano K; Patel S; Fisher CJ; Brown AK; Tunuguntla RH; Patel S; Sotillo E; Mackall CL; Feldman SA
Mol Cancer; 2023 Jun; 22(1):100. PubMed ID: 37365642
[TBL] [Abstract][Full Text] [Related]
3. CRISPR-Mediated Non-Viral Site-Specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy.
Odé Z; Condori J; Peterson N; Zhou S; Krenciute G
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604839
[TBL] [Abstract][Full Text] [Related]
4. Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
MacLeod DT; Antony J; Martin AJ; Moser RJ; Hekele A; Wetzel KJ; Brown AE; Triggiano MA; Hux JA; Pham CD; Bartsevich VV; Turner CA; Lape J; Kirkland S; Beard CW; Smith J; Hirsch ML; Nicholson MG; Jantz D; McCreedy B
Mol Ther; 2017 Apr; 25(4):949-961. PubMed ID: 28237835
[TBL] [Abstract][Full Text] [Related]
5. Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.
Tipanee J; Samara-Kuko E; Gevaert T; Chuah MK; VandenDriessche T
Mol Ther; 2022 Oct; 30(10):3155-3175. PubMed ID: 35711141
[TBL] [Abstract][Full Text] [Related]
6. Homology-Directed Recombination for Enhanced Engineering of Chimeric Antigen Receptor T Cells.
Hale M; Lee B; Honaker Y; Leung WH; Grier AE; Jacobs HM; Sommer K; Sahni J; Jackson SW; Scharenberg AM; Astrakhan A; Rawlings DJ
Mol Ther Methods Clin Dev; 2017 Mar; 4():192-203. PubMed ID: 28345004
[TBL] [Abstract][Full Text] [Related]
7. Adeno-Associated Viral Vectors for Homology-Directed Generation of CAR-T Cells.
Moço PD; Aharony N; Kamen A
Biotechnol J; 2020 Jan; 15(1):e1900286. PubMed ID: 31642193
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract][Full Text] [Related]
9. High-efficiency of genetic modification using CRISPR/Cpf1 system for engineered CAR-T cell therapy.
Ding R; Chao CC; Gao Q
Methods Cell Biol; 2022; 167():1-14. PubMed ID: 35152989
[TBL] [Abstract][Full Text] [Related]
10. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
[TBL] [Abstract][Full Text] [Related]
11. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
12. Production of Human CRISPR-Engineered CAR-T Cells.
Agarwal S; Wellhausen N; Levine BL; June CH
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33779622
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological interventions enhance virus-free generation of
Kath J; Du W; Pruene A; Braun T; Thommandru B; Turk R; Sturgeon ML; Kurgan GL; Amini L; Stein M; Zittel T; Martini S; Ostendorf L; Wilhelm A; Akyüz L; Rehm A; Höpken UE; Pruß A; Künkele A; Jacobi AM; Volk HD; Schmueck-Henneresse M; Stripecke R; Reinke P; Wagner DL
Mol Ther Methods Clin Dev; 2022 Jun; 25():311-330. PubMed ID: 35573047
[TBL] [Abstract][Full Text] [Related]
14. Optimization and validation of CAR transduction into human primary NK cells using CRISPR and AAV.
Naeimi Kararoudi M; Likhite S; Elmas E; Yamamoto K; Schwartz M; Sorathia K; de Souza Fernandes Pereira M; Sezgin Y; Devine RD; Lyberger JM; Behbehani GK; Chakravarti N; Moriarity BS; Meyer K; Lee DA
Cell Rep Methods; 2022 Jun; 2(6):100236. PubMed ID: 35784645
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
16. AAVS1 site-specific integration of the CAR gene into human primary T cells using a linear closed-ended AAV-based DNA vector.
Chen W; Tan L; Zhou Q; Li W; Li T; Zhang C; Wu J
J Gene Med; 2020 Apr; 22(4):e3157. PubMed ID: 31901177
[TBL] [Abstract][Full Text] [Related]
17. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
18. Engineering Tripartite Gene Editing Machinery for Highly Efficient Non-Viral Targeted Genome Integration.
Nam H; Xie K; Majumdar I; Yang S; Starzyk J; Lee D; Shan R; Li J; Wu H
Res Sq; 2023 Oct; ():. PubMed ID: 37961210
[TBL] [Abstract][Full Text] [Related]
19. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Eyquem J; Mansilla-Soto J; Giavridis T; van der Stegen SJ; Hamieh M; Cunanan KM; Odak A; Gönen M; Sadelain M
Nature; 2017 Mar; 543(7643):113-117. PubMed ID: 28225754
[TBL] [Abstract][Full Text] [Related]
20. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
